News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
341,911 Results
Type
Article (13883)
Company Profile (27)
Press Release (328001)
Section
Business (108753)
Career Advice (697)
Deals (20066)
Drug Delivery (38)
Drug Development (47061)
Employer Resources (69)
FDA (8504)
Job Trends (7023)
News (185624)
Policy (16173)
Tag
Academia (1116)
Alliances (23133)
Alzheimer's disease (791)
Approvals (8535)
Artificial intelligence (120)
Bankruptcy (172)
Best Places to Work (6157)
Breast cancer (117)
Cancer (1115)
Cardiovascular disease (69)
Career advice (593)
CAR-T (82)
Cell therapy (220)
Clinical research (39060)
Collaboration (367)
Compensation (77)
COVID-19 (1030)
C-suite (101)
Data (1193)
Diabetes (124)
Diagnostics (3342)
Earnings (54909)
Events (48560)
Executive appointments (297)
FDA (9107)
Funding (288)
Gene therapy (147)
GLP-1 (239)
Government (1908)
Healthcare (9110)
Infectious disease (1098)
Inflammatory bowel disease (72)
Interviews (101)
IPO (10419)
Job creations (1194)
Job search strategy (530)
Layoffs (103)
Legal (3039)
Lung cancer (173)
Lymphoma (77)
Manufacturing (115)
Medical device (6976)
Medtech (6977)
Mergers & acquisitions (9950)
Metabolic disorders (280)
Neuroscience (993)
NextGen: Class of 2025 (2645)
Non-profit (1732)
Northern California (1246)
Obesity (142)
Opinion (98)
Parkinson's disease (69)
Patents (104)
People (27495)
Phase I (11980)
Phase II (17058)
Phase III (13202)
Pipeline (569)
Postmarket research (1284)
Preclinical (4667)
Radiopharmaceuticals (152)
Rare diseases (169)
Real estate (2141)
Regulatory (12195)
Research institute (1033)
Resumes & cover letters (95)
Southern California (1108)
Startups (1251)
United States (10918)
Vaccines (232)
Weight loss (80)
Date
Today (71)
Last 7 days (474)
Last 30 days (1528)
Last 365 days (20487)
2025 (2986)
2024 (21122)
2023 (24319)
2022 (29776)
2021 (31984)
2020 (30289)
2019 (22980)
2018 (17385)
2017 (17952)
2016 (15795)
2015 (19403)
2014 (13570)
2013 (10453)
2012 (11172)
2011 (11998)
2010 (10741)
Location
Africa (368)
Asia (24933)
Australia (5626)
California (2840)
Canada (1182)
China (277)
Colorado (130)
Connecticut (149)
Europe (48374)
Florida (441)
Georgia (72)
Illinois (229)
Indiana (146)
Japan (102)
Maryland (395)
Massachusetts (2087)
Michigan (86)
Minnesota (155)
New Jersey (954)
New York (907)
North Carolina (478)
Northern California (1246)
Ohio (82)
Pennsylvania (665)
South America (593)
Southern California (1108)
Texas (415)
Utah (77)
Washington State (342)
341,911 Results for "mundipharma international limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. announced the execution of an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in the People’s Republic of China.
August 1, 2023
·
7 min read
Biotech Beach
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin.
April 24, 2024
·
4 min read
Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split
Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that an 1 for 5 reverse split of its authorized share capital, was approved by the Company’s board of directors on May 29, 2023 and will become effective on June 21, 2024.
June 18, 2024
·
4 min read
Press Releases
UTime Limited to Participate in International Medical Fairs and Medical Conferences
August 23, 2024
·
3 min read
Biotech Bay
Cutera Announces the International Limited Commercial Release of AviClear® at IMCAS World Congress 2024
CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced the international limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne.
February 8, 2024
·
4 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Biotech Beach
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
Cidara Therapeutics, Inc. announced receipt of an $11 million milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019.
October 4, 2022
·
4 min read
Press Releases
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
February 25, 2025
·
6 min read
Biotech Beach
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.
October 13, 2023
·
8 min read
1 of 34,192
Next
